Last updated: 2026-02-08 02:55:49 ET
Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two days after it announced the new drug
Hims & Hers on Saturday announced it would stop offering its copycat of the weight-loss pill Wegovy after threats of legal action.
Hims & Hers also said it’s selling a cancer-detection test that’s featured in its Super Bowl ad, which plays like a commentary on the wealthy’s ...
Hims & Hers stock fall to a 12-month low after Novo said it's $49 Wegovy pill copy was "illegal"
The new site is for people in the U.S. who are willing to pay out of pocket for certain brand-name medications, like Zepbound and Wegovy.
The compounded pill is less expensive than the oral version of Wegovy, which costs $149 to get started.
Novo Nordisk and Eli Lilly fell after Hims & Hers said it will offer a copy of the Wegovy pill for $49, far less than the $149 Novo sells the branded pill for.
Novo Nordisk is facing "unprecedented" price pressures, "intensifying competition" and patents expiring.
The maker of Ozempic and Wegovy blamed pricing pressures and competition for its downbeat outlook.
The company is banking on its Wegovy pill and next-generation weight loss injectable CagriSema to recapture share of the key U.S. market.
